Pub Date : 2021-02-16DOI: 10.2174/2212796815666210216101221
Avirup Malla, K. Mukherjee, M. Mandal, Aishwarya Mukherjee, R. Sur, Suvroma Gupta
Sulfamerazine, a sulfonamide, has been routinely used to treat various bacterial infections, namely Pneumonia, Urinary tract infections, Shigellosis, Bronchitis, Prostatitis, and many more. It interferes with the bacterial folic acid biosynthesis, albeit higher eukaryotes are not susceptible to its action due to the inherent absence of this specific pathway. In spite of its constant use, Sulfamerazine administration evokes serious issues like the development of antibacterial resistance through environmental contamination, although how it affects the eukaryotic system, specifically its target identification, has not been addressed in detail. The source of the cell line, including when and from where it was obtained. Whether the cell line has recently been authenticated and by what method. Whether the cell line has recently been tested for mycoplasma contamination. Hela Cells are cultured as per the standard method, amylase and lactate dehydrogenase assay are conducted using a standard procedure with a spectrophotometer. Binding thermodynamics and conformational study have been estimated with isothermal titration calorimetry as well as with docking. Experimental observations reveal that Sulfamerazine inhibits porcine pancreatic amylase in a noncompetitive mode (IC50 of 0.96 mM). The binding of the drug to porcine pancreatic amylase is entropy-driven with conformational changes of the protein as indicated by concomitant redshift. It enhances the inhibitory effects of acarbose and cetapin on their in vitro pancreatic amylase activity. It augments lipid peroxidation and promotes lactic acidosis in a dose-dependent manner. Docking studies ensure effective interactions between Sulfamerazine and proteins like lactic dehydrogenase and porcine pancreatic amylase. Detailed study is to be conducted to confirm whether the molecular scaffold of Sulfamerazine might serve as an effective repurposed drug acting as a lead molecule to design antidiabetic drugs of future use. Alternatively, it should be prescribed with caution under specific medical situations like diabetes, cancer and hepatic disorders manifesting lactic acidosis to avoid the crisis.
{"title":"An Insight to the Toxic Effect of Sulfamerazine on Porcine Pancreatic Amylase and Lactate Dehydrogenase Activity: An In Vitro Study","authors":"Avirup Malla, K. Mukherjee, M. Mandal, Aishwarya Mukherjee, R. Sur, Suvroma Gupta","doi":"10.2174/2212796815666210216101221","DOIUrl":"https://doi.org/10.2174/2212796815666210216101221","url":null,"abstract":"Sulfamerazine, a sulfonamide, has been routinely used to treat various bacterial\u0000infections, namely Pneumonia, Urinary tract infections, Shigellosis, Bronchitis, Prostatitis,\u0000and many more. It interferes with the bacterial folic acid biosynthesis, albeit higher eukaryotes are\u0000not susceptible to its action due to the inherent absence of this specific pathway.\u0000\u0000\u0000\u0000In spite of its constant use, Sulfamerazine administration evokes serious issues like the\u0000development of antibacterial resistance through environmental contamination, although how it affects\u0000the eukaryotic system, specifically its target identification, has not been addressed in detail.\u0000\u0000\u0000\u0000The source of the cell line, including when and from where it was obtained. Whether the\u0000cell line has recently been authenticated and by what method. Whether the cell line has recently\u0000been tested for mycoplasma contamination. Hela Cells are cultured as per the standard method,\u0000amylase and lactate dehydrogenase assay are conducted using a standard procedure with a spectrophotometer.\u0000Binding thermodynamics and conformational study have been estimated with\u0000isothermal titration calorimetry as well as with docking.\u0000\u0000\u0000\u0000Experimental observations reveal that Sulfamerazine inhibits porcine pancreatic amylase\u0000in a noncompetitive mode (IC50 of 0.96 mM). The binding of the drug to porcine pancreatic amylase\u0000is entropy-driven with conformational changes of the protein as indicated by concomitant redshift.\u0000It enhances the inhibitory effects of acarbose and cetapin on their in vitro pancreatic amylase\u0000activity. It augments lipid peroxidation and promotes lactic acidosis in a dose-dependent manner.\u0000Docking studies ensure effective interactions between Sulfamerazine and proteins like lactic dehydrogenase\u0000and porcine pancreatic amylase.\u0000\u0000\u0000\u0000 Detailed study is to be conducted to confirm whether the molecular scaffold of Sulfamerazine\u0000might serve as an effective repurposed drug acting as a lead molecule to design antidiabetic\u0000drugs of future use. Alternatively, it should be prescribed with caution under specific medical\u0000situations like diabetes, cancer and hepatic disorders manifesting lactic acidosis to avoid the crisis.","PeriodicalId":10784,"journal":{"name":"Current Chemical Biology","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90945263","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-02-03DOI: 10.2174/2212796815666210203104446
S. Banerjee, S. Amin, T. Jha
The term “hematological malignancy” means a cluster of cancer and tumor conditions, including leukemia, lymphoma, myeloproliferative neoplasm, lymphoproliferative disorders, etc., involved with circulatory organs like blood, bone marrow, lymph, and lymph nodes. The increase in the number of hematological malignancy-related cases in our modern society urges suitable treatment of such disease. In this current era, there is still a major deficiency in the number of suitable chemotherapeutic agents for the treatment of hematological malignancies. The researchers were successful in identifying various cellular, extracellular proteins, and cytokines, as well as their involvement in different hematological malignancies via epigenetic modulation and regulation of other proteins and signaling pathways. Here, we have discussed the structural aspects, connection, and pathophysiological contributions of a group of different cellular and extracellular proteins that are regulated and/or have a significant influence on the progression of different hematological malignancies along with their potent inhibitors. The correlation of physiological proteins with cancerous hematological conditions has been discussed here. It can be crucial for the development of potent inhibitors as chemotherapeutic agents to contest such malignancies. This review will also be useful in the chemotherapeutic agent development by providing crucial information about such hematological malignancy-related proteins and their inhibitors. The repurposed drugs with potential for anticancer applications are also discussed.
{"title":"Therapies of Hematological Malignancies: An Overview of the Potential Targets and Their Inhibitors","authors":"S. Banerjee, S. Amin, T. Jha","doi":"10.2174/2212796815666210203104446","DOIUrl":"https://doi.org/10.2174/2212796815666210203104446","url":null,"abstract":"\u0000\u0000The term “hematological malignancy” means a cluster\u0000of cancer and tumor conditions, including leukemia, lymphoma, myeloproliferative\u0000neoplasm, lymphoproliferative disorders, etc., involved with circulatory organs\u0000like blood, bone marrow, lymph, and lymph nodes.\u0000\u0000\u0000\u0000The increase in the number of hematological malignancy-related\u0000cases in our modern society urges suitable treatment of such disease. In this current\u0000era, there is still a major deficiency in the number of suitable chemotherapeutic\u0000agents for the treatment of hematological malignancies.\u0000\u0000\u0000\u0000The researchers were successful in identifying various cellular, extracellular\u0000proteins, and cytokines, as well as their involvement in different hematological\u0000malignancies via epigenetic modulation and regulation of other proteins\u0000and signaling pathways. Here, we have discussed the structural aspects, connection,\u0000and pathophysiological contributions of a group of different cellular and extracellular\u0000proteins that are regulated and/or have a significant influence on the\u0000progression of different hematological malignancies along with their potent inhibitors.\u0000\u0000\u0000\u0000The correlation of physiological proteins with cancerous\u0000hematological conditions has been discussed here. It can be crucial for the development\u0000of potent inhibitors as chemotherapeutic agents to contest such malignancies.\u0000This review will also be useful in the chemotherapeutic agent development\u0000by providing crucial information about such hematological malignancy-related\u0000proteins and their inhibitors. The repurposed drugs with potential for anticancer\u0000applications are also discussed.\u0000","PeriodicalId":10784,"journal":{"name":"Current Chemical Biology","volume":"34 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2021-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88312498","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2021-01-21DOI: 10.2174/2212796815666210121095445
Zeba Mueed, P. Rai, S. Siddique, N. Poddar
The advancements in cancer treatment have no significant effect on ovarian cancer [OC]. The lethality of the OC remains on the top list of gynecological cancers. The long term survival rate of the OC patients with the advanced stage is less than 30%. The only effective measure to increase the survivability of the patient is the detection of disease in stage I. The earlier the diagnosis, the more will be the chances of survival of the patient. But due to the absence of symptoms and effective diagnosis, only a few % of OC are detected in stage I. A valid, reliable having a high acceptance test is imperative to detect OC in its early stages. Currently, the most used approach for the detection of OC is the screening of CA-125 and transvaginal ultrasonography together. This approach has an efficacy of only 30-45%. A large number of biomarkers are also being explored for their potential use in the early screening of OC, but no success is seen so far. This review provides an overview of the biomarkers being explored for early-stage diagnosis of OC and increasing the current long-term survival rates of OC patients.
{"title":"Ovarian Cancer Biomarkers: Headway Towards Early Diagnosis","authors":"Zeba Mueed, P. Rai, S. Siddique, N. Poddar","doi":"10.2174/2212796815666210121095445","DOIUrl":"https://doi.org/10.2174/2212796815666210121095445","url":null,"abstract":"\u0000\u0000The advancements in cancer treatment have no significant effect on\u0000ovarian cancer [OC]. The lethality of the OC remains on the top list of gynecological\u0000cancers. The long term survival rate of the OC patients with the advanced\u0000stage is less than 30%. The only effective measure to increase the survivability\u0000of the patient is the detection of disease in stage I. The earlier the diagnosis, the\u0000more will be the chances of survival of the patient. But due to the absence of\u0000symptoms and effective diagnosis, only a few % of OC are detected in stage I. A\u0000valid, reliable having a high acceptance test is imperative to detect OC in its early\u0000stages. Currently, the most used approach for the detection of OC is the screening\u0000of CA-125 and transvaginal ultrasonography together. This approach has an\u0000efficacy of only 30-45%. A large number of biomarkers are also being explored\u0000for their potential use in the early screening of OC, but no success is seen so far.\u0000This review provides an overview of the biomarkers being explored for early-stage\u0000diagnosis of OC and increasing the current long-term survival rates of OC\u0000patients.\u0000","PeriodicalId":10784,"journal":{"name":"Current Chemical Biology","volume":"20 1","pages":"109-125"},"PeriodicalIF":0.0,"publicationDate":"2021-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82034782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}